STRIDE offers improved survival for hepatocellular carcinoma patients – but with the added risk of severe side effects. Credit: Shutterstock / Nemes Laszlo. AstraZeneca has
Cell therapies such as Lantidra could make type 1 diabetes much easier to manage – with or without insulin. Credit: Shutterstock / goffkein.pro. The US
If proven effective, Genprex’s Reqorsa could meet an unmet need for treatment in SCLC patients. Source: Shutterstock / Kateryna Kon Genprex has announced that the
Pfizer and OPKO’s Ngenla will be available in America, having already been approved in 40 other markets. Source: Shutterstock/ShU studio. Pfizer has announced that the
Adeno-associated virus gene therapies like Pfizer’s fidanacogene elaparvovec are set to become popular haemophilia treatments. Source: Getty Images / Motortion Pfizer has announced that the
Generalised myasthenia gravis is a rare condition – but UCB’s Rystiggo enters a competitive market. Source: Shutterstock / Giovanni Cancemi. Belgian biopharmaceutical company UCB has
Pulmonary Arterial Hypertension patients are often restricted to complicated and difficult to adhere to treatment regimes. Source: Getty Images / FG Trade Johnson & Johnson’s
Pfizer’s Litfulo is one of the first approved treatments for an often neglected disease. Source: Shutterstock / meyer_solutions. The US Food and Drug Administration (FDA)
AbbVie’s Qulipta could bring relief to over 40 million migraine sufferers in Europe. Source: Shutterstock / Tunatura. AbbVie announced the European Medicines Agency’s (EMA) Committee
IRBM claims its partnership with MSD has benefitted from recent advances in phage and mRNA display platforms. Source: Shutterstock / testing. Contract research organisation IRBM